Mechanism of immune suppression by allogeneic blood transfusion in patients with gastrointestinal cancer.

异基因输血是否会对接受异基因输血的患者的存活率或术后感染产生不良影响，这一点与未接受异基因输血的患者相比存在争议。本文回顾分析了121例胃肠癌根治术患者的存活率：异体血18例，自体血33例，未输血患者70例(胃癌66例，结肠癌29例，直肠癌26例)。我们比较了三组患者的三年生存率，自体输血组的86.3%与非输血组的88.1%相当，但高于异体输血组的76.6%，但不显著。对8例根治性手术患者的免疫指标、自然杀伤细胞活性和淋巴细胞亚群的变化进行了分析。而术后NAD组、异体输血组、自体输血组和未输血组之间的差异无统计学意义。综上所述，输血对癌症患者的生存和免疫指标的影响尚未得到证实。一项大规模的多中心研究是必要的。

Whether allogeneic blood transfusion gives rise to adverse effect on survival or postoperational infection in patients who received allogeneic blood as compared with those who did not received is controversial. We studied retrospetively survival rate in patients who underwent radical operation for gastrointestinal cancer : 18 allogeneic blood, 33 autologous blood, and 70 no blood transfusion (66 gastric cancer, 29 colon cancer, and 26 rectal cancer), a total of 121 cancer patients were analyzed. We compared 3-year survival rate of the three patient groups ; 86.3% in autologous transfusion group was comparable with 88.1% of no transfusion group but higher, although not significantly, than 76.6% in allogeneic transfusion group. We also analyzed the change of immunological markers, natural killer cell activities and lymphocyte subsets in 8 patients undergoing radical operation. However, we could not find any significant differences among before nad after operation, and among the groups of allogeneic, autologous, and no transfusion. In conclusion, the effects of blood transfusion on survival and immunological markers of the patients with cancer were not demonstrated. A large-scale multi-center study is warranted.